StreetInsider.com News Articles

Mizuho defends Immuneering Corporation (IMRX), 'recommend being opportunistic on IMRX'

Tue, 02 Jun 2026 06:43:27 -0400

Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $12.00 price target on Immuneering Corporation (NASDAQ: IMRX).

The analyst commented: "With shares -20-25% intraday (vs. -2% XBI) today, we reiterate our Outperform rating on IMRX, following its data update this morning for lead asset atebimetinib/atebi in 1L metastatic PDAC, representing a more robust update from 55 patients (vs. prior 34 pts). While the headline 17.3-month median overall survival/OS was previously disclosed (on 5/21), in our view, the main punchlines were that, encouragingly, both efficacy and safety/tolerability profiles for atebi were maintained — this represents a positive update. We believe intra-day weakness

Form 8-K Immuneering Corp For: Jun 01

Mon, 01 Jun 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260601/26584719.html

Form 8-K Immuneering Corp For: Jun 01

Mon, 01 Jun 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260601/26584719.html

Form 8-K Immuneering Corp For: Jun 01

Mon, 01 Jun 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260601/26584719.html

Form 8-K Immuneering Corp For: Jun 01

Mon, 01 Jun 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260601/26584719.html

Oppenheimer Reiterates Outperform Rating on Immuneering Corporation (IMRX) Following Data

Mon, 01 Jun 2026 09:59:43 -0400

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $30.00 price target on Immuneering Corporation (NASDAQ: IMRX) after the company reported 17.3-month survival data for pancreatic cancer drug/

The analyst commented, "Following RVMD's presentation of details from the RASolute-302 study during a plenary session at ASCO2026, with daraxonrasib doubling the median OS vs. chemo comparator in previously treated mPDAC patients, IMRX provided updates from the Ph2a study of atebimetinib + mGnP. Promising signals suggest significant improvement in overall survival in 1L PDAC patients. Overall, the latest update highlights an encouraging 17.3 months mOS across 55 PDAC patients, comparing favorably against historical

Immuneering reports 17.3-month survival data for pancreatic cancer drug

Mon, 01 Jun 2026 07:31:07 -0400

Immuneering Corporation (NASDAQ: IMRX) reported clinical trial results showing a median overall survival of 17.3 months for patients with first-line metastatic pancreatic cancer treated with its drug candidate atebimetinib combined with chemotherapy.

The data from 55 patients in an ongoing Phase 2a trial were presented at the American Society of Clinical Oncology Annual Meeting. The company compared the results to 8.5 months median overall survival reported in the MPACT study of standard chemotherapy alone.

The trial evaluated atebimetinib at 320 mg once daily combined with modified gemcitabine/nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. Median progression-free survival was 8.3 months, with a

Immuneering reports 17.3-month survival data for pancreatic cancer drug

Mon, 01 Jun 2026 07:31:07 -0400

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Mon, 01 Jun 2026 07:30:00 -0400

- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study -

- Only two categories of Grade 3+ treatment-related adverse events occurring in ≥10% of patients, both chemotherapy related -

- 84% of participants maintained or gained weight at three months -

- Global Phase 3 MAPKeeper 301 trial (NCT07562152) in first-line metastatic pancreatic cancer actively recruiting, with first patient dosing expected in mid-2026 -

- Company to hold investor conference call today, at 8:00 a.m.

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Mon, 01 Jun 2026 07:30:00 -0400

- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study -

- Only two categories of Grade 3+ treatment-related adverse events occurring in ≥10% of patients, both chemotherapy related -

- 84% of participants maintained or gained weight at three months -

- Global Phase 3 MAPKeeper 301 trial (NCT07562152) in first-line metastatic pancreatic cancer actively recruiting, with first patient dosing expected in mid-2026 -

- Company to hold investor conference call today, at 8:00 a.m.

Immuneering reports 17.3-month survival in pancreatic cancer trial

Thu, 21 May 2026 17:02:18 -0400

Immuneering Corporation (NASDAQ: IMRX) reported a median overall survival of 17.3 months in first-line metastatic pancreatic cancer patients treated with atebimetinib plus modified gemcitabine/nab-paclitaxel in its Phase 2a clinical trial, based on data as of April 24, 2026.
The study included 55 patients, with detailed results scheduled for presentation at the American Society of Clinical Oncology Annual Meeting on June 1, 2026. The treatment showed a tolerability profile with only two categories of Grade 3 or higher treatment-related adverse events observed in 10% or more of patients: anemia at 16% and neutropenia at 18%, both related to chemotherapy components.
Peter Vu of

Immuneering reports 17.3-month survival in pancreatic cancer trial

Thu, 21 May 2026 17:02:18 -0400

Immuneering Corporation (NASDAQ: IMRX) reported a median overall survival of 17.3 months in first-line metastatic pancreatic cancer patients treated with atebimetinib plus modified gemcitabine/nab-paclitaxel in its Phase 2a clinical trial, based on data as of April 24, 2026.
The study included 55 patients, with detailed results scheduled for presentation at the American Society of Clinical Oncology Annual Meeting on June 1, 2026. The treatment showed a tolerability profile with only two categories of Grade 3 or higher treatment-related adverse events observed in 10% or more of patients: anemia at 16% and neutropenia at 18%, both related to chemotherapy components.
Peter Vu of

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Thu, 21 May 2026 17:00:00 -0400

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 -

- Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related -

- Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST -

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Thu, 21 May 2026 17:00:00 -0400

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 -

- Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related -

- Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST -

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Thu, 21 May 2026 17:00:00 -0400

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 -

- Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related -

- Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST -

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Thu, 21 May 2026 17:00:00 -0400

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 -

- Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related -

- Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST -

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Thu, 21 May 2026 17:00:00 -0400

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 -

- Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related -

- Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST -

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Thu, 21 May 2026 17:00:00 -0400

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 -

- Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related -

- Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST -

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Thu, 21 May 2026 17:00:00 -0400

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 -

- Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related -

- Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST -

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Thu, 21 May 2026 17:00:00 -0400

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 -

- Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related -

- Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST -

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Thu, 21 May 2026 17:00:00 -0400

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 -

- Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related -

- Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST -

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Thu, 21 May 2026 17:00:00 -0400

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 -

- Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related -

- Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST -

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Thu, 21 May 2026 17:00:00 -0400

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 -

- Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related -

- Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST -

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Thu, 21 May 2026 17:00:00 -0400

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 -

- Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related -

- Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST -

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Thu, 21 May 2026 17:00:00 -0400

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 -

- Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related -

- Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST -

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them